Noopept vs PT-141
Moderate Research vs FDA Approved
monitor Mechanism-based · 51% Both Noopept and PT-141 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Noopept PT-141
Weight 318.37 Da —
Half-life ~30 minutes (oral), active metabolite cycloprolylglycine persists longer ~2.7 hours
Type Dipeptide derivative (C17H22N2O4) Melanocortin receptor agonist
Key Benefits
Noopept
01 Enhanced memory formation and consolidation through upregulation of BDNF and NGF
02 Neuroprotective effects against oxidative stress, excitotoxicity, and amyloid-beta toxicity
03 Improved learning capacity and information retrieval via AMPA/NMDA receptor modulation
04 Ultra-low effective dose (10-30 mg) compared to classical racetams, reducing pill burden and cost
05 Anxiolytic properties observed at standard nootropic doses without sedation
06 Fast onset of subjective effects despite the short parent compound half-life, due to active metabolite persistence
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Dosing Protocols
Noopept
10-30 mg/day / Split AM/PM (sublingual or oral)
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Side Effects
Noopept
Headache (most common side effect, typically caused by insufficient choline intake -- co-supplementation with Alpha-GPC or CDP-Choline usually resolves this)
Irritability and restlessness, particularly at doses exceeding 30 mg/day
Insomnia if taken too late in the day
Mild gastrointestinal discomfort when taken on an empty stomach
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Contraindications
Known hypersensitivity to Noopept or related compounds
Severe hepatic impairment (metabolized by the liver)
Severe renal impairment
Pregnancy and breastfeeding (insufficient safety data)
Hypertension that is poorly controlled (due to potential mild pressor effects)
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Research Evidence
Noopept PT-141
Status Moderate Research FDA Approved
References 4 studies 4 studies
Latest — 2022
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.